iShares US Pharmaceuticals ETF
98 hedge funds and large institutions have $148M invested in iShares US Pharmaceuticals ETF in 2018 Q3 according to their latest regulatory filings, with 16 funds opening new positions, 22 increasing their positions, 30 reducing their positions, and 11 closing their positions.
81% more call options, than puts
Call options by funds: $3.56M | Put options by funds: $1.96M
45% more first-time investments, than exits
New positions opened: 16 | Existing positions closed: 11
11% more capital invested
Capital invested by funds: $133M → $148M (+$14.3M)
3% more funds holding
Funds holding: 95 → 98 (+3)
13.83% less ownership
Funds ownership: 111.28% → 97.45% (-14%)
27% less repeat investments, than reductions
Existing positions increased: 22 | Existing positions reduced: 30
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
CIBC World Market
Toronto,
Ontario, Canada
|
+$4.01M |
| 2 |
Citadel Advisors
Miami,
Florida
|
+$2.88M |
| 3 |
RWP
RWA Wealth Partners
Newton,
Massachusetts
|
+$2.01M |
| 4 |
Jane Street
New York
|
+$1.36M |
| 5 |
Bank of America
Charlotte,
North Carolina
|
+$1.07M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
-$5.59M |
| 2 |
Royal Bank of Canada
Toronto,
Ontario, Canada
|
-$3.22M |
| 3 |
Ameriprise
Minneapolis,
Minnesota
|
-$2.24M |
| 4 |
FPGK
Financial Partners Group (Kansas)
Overland Park,
Kansas
|
-$2.14M |
| 5 |
CWM
Cornerstone Wealth Management
St. Peters,
Missouri
|
-$1.89M |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
101
Simplex Trading
Chicago,
Illinois
| – | -$103K | -2,049 | Closed |
|
102
Manulife (Manufacturers Life Insurance)
Canada,
Ontario, Canada
| – | -$58K | -1,158 | Closed |
|
|
AWA
103
Acorn Wealth Advisors
Grand Blanc,
Michigan
| – | -$38K | -750 | Closed |
|
|
BWA
104
BDO Wealth Advisors
Jacksonville,
Florida
| – | -$21K | -420 | Closed |
|
|
JCM
105
Jacobi Capital Management
Pittston,
Pennsylvania
| – | -$17K | -330 | Closed |
|
|
CF
106
Centaurus Financial
Anaheim,
California
| – | -$16K | -318 | Closed |
|
|
CG
107
Cutler Group
San Francisco,
California
| – | -$15K | -300 | Closed |
|
|
WIM
108
Westside Investment Management
Santa Monica,
California
| – | -$8.31K | -165 | Closed |
|
IHE Hedge Fund Activity: Q3 2018 in Review
98 of the 4,374 institutional investors tracked by Wall St. Rank reported a position in iShares US Pharmaceuticals ETF (IHE) for Q3 2018, worth a combined $148M — up 11% from $133M a quarter earlier.
Buyers outnumbered sellers: 16 funds opened new IHE positions and 11 closed out — a net gain of 5 holders — while 22 added to existing stakes and 30 trimmed.
The largest buyer was CIBC World Market, opening a new position worth an estimated $4.01M. The largest seller was Susquehanna International Group, cutting an estimated $5.59M.
- 98 institutional investors held iShares US Pharmaceuticals ETF (IHE) as of Q3 2018, up from 95 in Q2 2018.
- Funds reported $148M of iShares US Pharmaceuticals ETF stock for Q3 2018, up 11% quarter-over-quarter.
- 16 funds opened new iShares US Pharmaceuticals ETF positions in Q3 2018 and 11 closed out, a net change of +5 holders.
- The largest iShares US Pharmaceuticals ETF buyer in Q3 2018 was CIBC World Market, an estimated $4.01M added.
- The largest iShares US Pharmaceuticals ETF seller in Q3 2018 was Susquehanna International Group, an estimated $5.59M sold.
Based on aggregated 13F filings for Q3 2018.